Global Osteoarthritis Drug Market to Surpass US$16,184.9 Million by 2030


SEATTLE, September 5, 2022 /PRNewswire/ — According to Consistent market informationthe Global osteoarthritis drug market is estimated at US$8,592.2 million in 2022 and should present a 8.2% CAGR during the forecast period (2022-2030).

Key Trends and Analysis of the Global Osteoarthritis Drugs Market:

The growing number of launches by market players for osteoarthritis treatment is expected to drive the growth of the global osteoarthritis drug market over the forecast period. For example, in May 2020, Kitov Pharma Ltd., a clinical-stage company, announced the commercial launch in the United States of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, designed for the simultaneous treatment of hypertension and pain osteoarthritis. Consensi is sold in the United States by Burke Therapeutics, a pharmaceutical company, a marketing partner of Kitov’s US distributor, Coeptis Pharmaceuticals, a biopharmaceutical company.

Increasing research and development by osteoarthritis market players is expected to drive the growth of the global osteoarthritis drugs market over the forecast period. For example, in December 2021, Radius Health, Inc., a biotechnology company, announced the first phase 3 results of the wearABLe study evaluating the non-inferiority (NI) of the abaloparatide transdermal system (abalo-TDS) compared to injection of abaloparatide (TYMLOS) in postmenopausal women with osteoporosis. The wearABLe study did not meet its NI primary endpoint for abalo-TDS 300 micrograms (ug) versus TYMLOS 80 ug in percent change from baseline in bone mineral density ( BMD) of the lumbar spine (LS) at 12 months based on an NI margin of 2.0%. While data and technical details from the wearABLe study should be analyzed and used as the basis for future abalo-TDS plans.

The increase in US FDA (Food and Drug Administration) drug approval in the treatment of osteoarthritis is expected to drive the growth of the global osteoarthritis drug market during the forecast period. For example, in September 2021, FDA Grants Fast Track Status to Novartis, a Global Healthcare Company, LNA043 for Osteoarthritis of the Knee. An ANGPTL3 agonist, the drug targets damaged cartilage to induce its regeneration. LNA043 is an angiopoietin-like 3 (ANGPTL3) agonist.

Request a sample copy of this report @

Main market takeaways:

Among drug classes, the nonsteroidal anti-inflammatory drugs (NSAIDs) segment occupied a dominant position in the osteoarthritis drug market, owing to the increasing use of NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) in the treatment of arthritis patients in the market over the forecast period. For example, in September 2021according to reports published by Research Gate, a social networking service, based on the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, regulatory agency websites and since its inception until June 28, 2021which indicates that etoricoxib 60 mg/day and diclofenac 150 mg/day appear to be the most effective oral NSAIDs for osteoarthritis pain, whereas topical diclofenac 70-81 mg/day may be effective and safer due to reduced systemic exposure and lower dose, and should be considered first-line pharmacological treatment for knee osteoarthritis.

North America is expected to hold the largest share of the global osteoarthritis drugs market and is expected to exhibit a 8.2% CAGR over the forecast period (2022-2030), owing to the growing number of organic growth strategies such as acquisition by market players, is expected to drive the growth of the global Osteoarthritis Drugs market over the course of the forecast period. For example, in December 2021Avanos Medical, Inc., a medical technology company, announced that it has entered into a definitive agreement to acquire OrthogenRx, Inc., a medical device company, for total consideration of $160 million. The purchase price includes $130 million cash at closing plus a surcharge $30 million in conditional cash consideration, payable upon completion of the Company’s commercial hyaluronic acid (HA) therapeutic products, GenVisc 850 and TriVisc. This acquisition will help the company continue its expansion by providing a continuum of care treatment options for patients with osteoarthritis of the knee (osteoarthritis).

Key players operating in the global Osteoarthritis Drugs market include Pfizer, Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA SpA, Horizon Therapeutics plc, Ferring BV, Merck Sharp & Dohme Corp., Medivir, Bioventus, Sanofi, Regeneron, GlaxoSmithKline Plc., Johnson & Johnson Private Limited, Bayer AG , Novartis AG, Ferring BV, Pacira Pharmaceuticals, Inc., Zimmer Biomet, OrthogenRx, Inc. and PHARMED LTD.

Customization request @

Detailed segmentation:

Global Osteoarthritis Drugs Market, By Drug Class:

    • Painkillers
    • Nonsteroidal anti-inflammatory drugs
    • Corticosteroids
    • Hyaluronic acid
    • Phase III drugs

Global Osteoarthritis Drugs Market, By Administration:

Global Osteoarthritis Drugs Market, By Disease Type:

    • Ankle osteoarthritis
    • Hip osteoarthritis
    • Osteoarthritis of the knee
    • Shoulder osteoarthritis
    • Others (vertebral osteoarthritis and cervical osteoarthritis)

Global Osteoarthritis Drugs Market, By Distribution Channel:

    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies

Global Osteoarthritis Drug Market, By Region:

  • North America
  • Europe
    • By country:
      • UK
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East & Africa
    • By country:
      • GCC countries
      • Israel
      • South Africa
      • Rest of Middle East & Africa

Buy this full report now @

About Us:

Consistent market information is a global market intelligence and advisory organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office at Indiahaving a sales office in the financial capital of the world in the United States and sales advisers in UK and Japan. Our customer base includes players from various industries in more than 57 countries around the world. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insights in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Contact us:

Mr Shah
Senior Client Partner – Business Development
Consistent market information
WE: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
E-mail: [email protected]
Follow us: LinkedIn | Twitter


SOURCE Consistent Market Information


About Author

Comments are closed.